

ACCELERATED COMMUNICATION

**High constitutive activity accounts for the combination of enhanced direct activation and
reduced potentiation in mutated GABA_A receptors**

Allison L. Germann, Daniel J. Shin, Christina R. Kuhrau, Alexander D. Johnson, Alex S. Evers, and
Gustav Akk

Department of Anesthesiology (ALG, DJS, CRK, ADJ, ASE, GA), and the Taylor Family Institute for
Innovative Psychiatric Research (ASE, GA), Washington University School of Medicine, St. Louis,
MO, USA,

Running title: Effect of constitutive activity on potentiation

Correspondence: Gustav Akk, Department of Anesthesiology, Washington University School of
Medicine, Campus Box 8054, 660 S. Euclid Ave, St. Louis, MO 63110, USA. Email:
akk@morpheus.wustl.edu

Number of text pages: 26

Number of tables: 0

Number of figures: 6

Number of references: 31

Number of words:

Abstract: 237

Introduction: 515

Discussion: 1125

Abbreviations: $EC_{5\%}$, a response with peak amplitude of 5% of the response to saturating GABA;
 c_{GABA} , a measure of gating efficacy in the presence of GABA; c_{PRO} , a measure of gating efficacy in the
presence of propofol; $GABA_A$ receptor, γ -aminobutyric acid type A receptor; K_{GABA} , equilibrium
dissociation constant of the closed receptor to GABA; K_{PRO} , equilibrium dissociation constant of the
closed receptor to propofol; $P_{o,const}$, open probability of constitutively active receptors

Abstract

GABA_A receptors activated by the transmitter GABA are potentiated by several allosterically acting drugs including the intravenous anesthetic propofol. Propofol can also directly activate the receptor, albeit at higher concentrations. Previous functional studies have identified amino acid residues whose substitution reduces potentiation of GABA-activated receptors by propofol while enhancing the ability of propofol to directly activate the receptor. One interpretation of such observations is that the mutation has specific effects on the sites or processes involved in potentiation or activation. We show here that divergent effects on potentiation and direct activation can be mediated by increased constitutive open probability in the mutant receptor without any specific effect on the interactions between the allosteric drug and the receptor. By simulating GABA_A receptor activity using the concerted transition model we show that the predicted degree of potentiation is reduced as the level of constitutive activity increases. The model further predicts that a potentiating effect of an allosteric modulator is a computable value that depends on the level of constitutive activity, the amplitude of the response to the agonist, and the amplitude of the direct activating response to the modulator. Specific predictions were confirmed by electrophysiological data from the binary $\alpha 1\beta 3$ and concatemeric ternary $\beta 2\alpha 1\gamma 2L + \beta 2\alpha 1$ GABA_A receptors. The corollaries of reduced potentiation due to increased constitutive activity are isobolograms that conform to simple additivity and a loss of separation between the concentration-response relationships for direct activation and potentiation.

Introduction

The γ -aminobutyric acid type A (GABA_A) receptor is a member of the Cys-loop superfamily of transmitter-gated ion channels sharing functional and structural features with other members of the family, such as the nicotinic acetylcholine receptor, the glycine receptor and the 5-hydroxytryptamine type 3 receptor (Bouzat, 2012). The GABA_A receptor is the major transmitter-gated inhibitory ion channel in the brain and a target for several clinically important drugs including the intravenous anesthetic propofol. Wild-type GABA_A receptors activated by the transmitter GABA are potently and efficaciously potentiated by propofol. Propofol can also directly activate the receptor in the absence of GABA; however, the concentration-response relationship for direct activation is shifted to higher propofol concentrations compared to that for potentiation of GABA-activated receptors (Hales and Lambert, 1991; Ruesch et al., 2012).

Propofol acts allosterically, i.e., by interacting with sites distinct from the orthosteric transmitter binding site (Jayakar et al., 2014; Yip et al., 2013). Functional studies have identified regions where amino acid substitutions modify the actions of propofol (Carlson et al., 2000; Eaton et al., 2015; Krasowski et al., 2001; Richardson et al., 2007; Thompson et al., 1999). Interestingly, in some cases the mutations differentially modify the potentiating and activating effects of propofol. For example, receptors containing the β 2(G219F) mutation are directly activated by propofol but show little enhancement of GABA-elicited currents by propofol or another allosteric modulator pentobarbital (Carlson et al., 2000). Similarly, the L9'S mutation in the TM2 domain of the β 2 subunit generates receptors that are highly sensitive to GABA or propofol separately, but show little enhancement of the current response when GABA is combined with the allosteric agent (Thompson et al., 1999).

Disparate effects of a mutation on potentiation and direct activation have served as basis to hypothesize that distinct sites or structural requirements underlie the potentiating and activating actions of a drug (Carlson et al., 2000). This, however, appears incompatible with the concerted transition model that dictates that the same site(s) mediate both actions, and which has been

successfully used to describe wild-type GABA_A receptor activation and modulation by propofol (Ruesch et al., 2012; Shin et al., 2018).

A common feature of the mutated GABA_A receptors showing opposing effects on potentiation and activation is a high level of constitutive activity, i.e., channel activity in the absence of any GABAergic agonists. It is well understood that increased constitutive activity correlates with lower EC₅₀ for direct activation. The relationship between the two can be expressed through the state function in the concerted transition model for receptor activation (Forman, 2012; Karlin, 1967; Monod et al., 1965), which is in good agreement with the experimentally established relationship between EC₅₀ and constitutive activity (Akk et al., 2018; Chang and Weiss, 1999). To test whether high level of constitutive activity can account for reduced potentiation of the GABA_A receptor by allosteric agents, we have conducted series of simulations of current responses using the concerted transition model. The simulations indicate that increased constitutive activity correlates with reduced potentiation. The model-based predictions were verified by experimental data from binary and ternary GABA_A receptors.

Materials and Methods

Receptor expression

The wild-type and mutant GABA_A receptors were expressed in *Xenopus* oocytes. Harvesting of oocytes was conducted under the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. The animal protocol was approved by the Animal Studies Committee of Washington University in St. Louis.

The receptors were expressed as binary receptors consisting of human $\alpha 1$ and $\beta 3$ subunits, or as concatemeric ternary receptors consisting of $\beta 2$ - $\alpha 1$ - $\gamma 2L$ and $\beta 2$ - $\alpha 1$ constructs of rat origin. The generation and properties of concatemeric receptors have been described previously (Akk et al., 2018; Bracamontes et al., 2011; Bracamontes and Steinbach, 2009). The mutations ($\beta 3(Y143W)$ and $\alpha 1(L263S)$) were made using the QuikChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA), and the coding region fully sequenced prior to use. The cDNAs subcloned in the pcDNA3 vector were linearized with Xba I (NEB Labs, Ipswich, MA), and the cRNAs generated using mMessage mMachine (Ambion, Austin, TX). The oocytes were injected with a total of 10-12 ng cRNA (in 5:1 ratio for $\alpha 1:\beta 3$ subunits or 1:1 ratio for concatemeric constructs) and incubated in ND96 with supplements (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂, 2.5 mM Na pyruvate, 5 mM HEPES, and 100 U/ml+100 μ g/ml penicillin+streptomycin and 50 μ g/ml gentamycin; pH 7.4) at 16 °C for 1-3 days before conducting electrophysiological recordings.

Electrophysiology

The electrophysiological recordings were conducted using the standard two-electrode voltage clamp technique. The oocytes were clamped at -60 mV. The chamber (RC-1Z, Warner Instruments, Hamden, CT) was perfused continuously at 5-8 ml min⁻¹ with ND96. Solutions were gravity-applied from 30-ml glass syringes with glass luer slips via Teflon tubing to reduce adsorption, and were

switched manually. A typical experiment consisted of recording of a 10-s baseline, then a 20-60 s drug application, followed by bath (ND96) application until full recovery. The current responses were amplified with an Axoclamp 900A (Molecular Devices, Sunnyvale, CA) or OC-725C amplifier (Warner Instruments, Hamden, CT), digitized with a Digidata 1320 or 1200 series digitizer (Molecular Devices), and stored using pClamp (Molecular Devices). The current traces were analyzed using Clampfit (Molecular Devices) to determine peak amplitude.

Data analysis

In experiments involving responses to single concentrations of agonists and combinations of agonists, the effect of a potentiator is expressed as the potentiation response ratio, calculated as the peak response to GABA + potentiator (propofol or pentobarbital) divided by the peak response to GABA alone. The findings are expressed as mean \pm S.D. (number of cells).

Modulation by propofol was also examined by measuring the effect of coapplication of a low concentration of propofol on the GABA concentration-response relationship. The concentration-response curves were fitted to the following equation:

$$Y = Y_{\min} + (Y_{\max} - Y_{\min}) \times \frac{[\text{GABA}]^{n_H}}{[\text{GABA}]^{n_H} + EC_{50}^{n_H}} \quad (\text{Eq. 1})$$

where EC_{50} is the concentration of GABA producing a half-maximal effect, n_H is the Hill slope, and Y_{\min} and Y_{\max} are the low- and high-concentration asymptotes, respectively. The fitting parameters were determined individually for each cell. The results are given as mean \pm S.D. (number of cells).

Simulations of current responses

To simulate current responses, we employed the state function of the receptor (Chang and Weiss, 1999; Ruesch et al., 2012):

$$P_o = \frac{1}{1 + L \times \left[\frac{1 + [\text{agonist}]/K}{1 + [\text{agonist}]/cK} \right]^N} \quad (\text{Eq. 2})$$

where P_o is the open probability of the receptor (or, for a population of receptors, the fraction of receptors in the active states), K is the equilibrium dissociation constant of the closed receptor for the agonist (GABA or propofol), N corresponds to the number of binding sites, and the parameter c is a measure of gating efficacy that can be expressed as the ratio of the open receptor equilibrium dissociation constant to the closed receptor equilibrium dissociation constant. L is the equilibrium gating constant of the unliganded receptor and is related to the probability that an unliganded receptor is constitutively active ($P_{o,\text{const}}$) through $L = (1 - P_{o,\text{const}})/P_{o,\text{const}}$.

To simulate responses to GABA or propofol individually, the values of K_{GABA} , c_{GABA} (affinity and efficacy measures in the presence of GABA) and K_{PRO} and c_{PRO} (affinity and efficacy measures in the presence of propofol) for the $\alpha 1\beta 3$, $\alpha 1\beta 3(\text{Y143W})$, and $\beta 2\alpha 1\gamma 2\text{L} + \beta 2\alpha 1$ receptors taken from previous reports (Akk et al., 2018; Eaton et al., 2016; Shin et al., 2018) were used in Eq. 2. For the $\alpha 1\beta 3$ wild-type receptor, K_{GABA} was 1.6 μM , c_{GABA} was 0.02, K_{PRO} was 4.7 μM and c_{PRO} was 0.24. For $\alpha 1\beta 3(\text{Y143W})$, K_{GABA} was 2.8 μM , c_{GABA} was 0.02, K_{PRO} was 23 μM and c_{PRO} was 0.27. For the $\beta 2\alpha 1\gamma 2\text{L} + \beta 2\alpha 1$ receptor, K_{GABA} was 72 μM , c_{GABA} was 0.0033, K_{PRO} was 21 μM and c_{PRO} was 0.22.

To simulate a response to the combination of GABA + propofol, Eq. 2 was modified to incorporate gating by propofol as background activity:

$$P_o = \frac{1}{1 + L^* \times \left[\frac{1 + [\text{GABA}]/K_{\text{GABA}}}{1 + [\text{GABA}]/c_{\text{GABA}} K_{\text{GABA}}} \right]^{N_{\text{GABA}}}} \quad (\text{Eq. 3})$$

In this equation, L^* is a modified equilibrium gating constant reflecting background activity in the presence of propofol that can be formally expressed as:

$$L^* = L \times \left[\frac{1 + [\text{propofol}] / K_{\text{PRO}}}{1 + [\text{propofol}] / c_{\text{PRO}} K_{\text{PRO}}} \right]^{N_{\text{PRO}}} \quad (\text{Eq. 4})$$

In practice, L^* was calculated from receptor open probability in the presence of propofol as:

$$L^* = (1 - P_{o,\text{PRO}}) / P_{o,\text{PRO}} \quad (\text{Eq. 5})$$

To express current responses as fractional values, the concentration-response relationships simulated in units of open probability were normalized using the following equation:

$$\text{Fractional response} = \frac{P_o - P_{o,\text{const}}}{P_{o,\text{max}} - P_{o,\text{const}}} \quad (\text{Eq. 6})$$

where P_o , $P_{o,\text{const}}$, and $P_{o,\text{max}}$ reflect open probability at a given agonist concentration, open probability of constitutively active receptors, and maximal open probability in the presence of the given agonist, respectively.

To predict the potentiation response ratios, we first simulated the GABA and propofol concentration-response curves using Eqs. 2 and 6. The experimental fractional response to propofol was converted to units of open probability (Shin et al., 2018), from which L^* was calculated using Eq. 5. The response to the combination of GABA + propofol was subsequently estimated as activation by GABA at modified L^* , using Eq. 3. The response to the combination of GABA + propofol could also be modeled by calculating the response to propofol in the presence of background activity elicited by GABA. Both approaches yielded identical results (not shown). The response to the combination of GABA + pentobarbital was modeled by determining the response to GABA in the presence of background activity due to pentobarbital.

The nominal concentrations of GABA and propofol used in the specific experiments were adjusted to generate responses with peak amplitudes equal to the experimental values. In other words, the calculations utilizing experimental data reflect responses to combinations of GABA and propofol at actual, experimental EC values rather than to combinations of specific concentrations of GABA and propofol. This was done to negate any influence of day-to-day experimental variability.

Results

Propofol is a weak potentiator of the $\alpha 1\beta 3(Y143W)$ receptor

Propofol allosterically activates GABA_A receptors and potentiates GABA-elicited currents (Hales and Lambert, 1991; Ruesch et al., 2012). In oocytes expressing the wild-type $\alpha 1\beta 3$ receptor, the application of 1 μ M propofol elicited a current response with the mean peak amplitude that was ~0.4% of the peak response to saturating GABA. Coapplication of 1 μ M propofol with 0.3 μ M GABA (EC₅) potentiated the current response by 4.2 ± 1.6 -fold (mean \pm S.D.; ratio of peak responses to GABA + propofol / GABA; n = 6 cells).

The $\alpha 1\beta 3$ receptors containing the Y143W mutation in the $\beta 3$ subunit are potently and efficaciously activated by GABA and propofol (Eaton et al., 2016). However, potentiation of GABA-elicited currents by propofol is reduced. In the $\alpha 1\beta 3(Y143W)$ receptor, the application of 0.1 μ M propofol, that by itself generated a response with the mean peak amplitude of 1.7% of the response to saturating GABA, potentiated the peak response to 0.02 μ M GABA (EC₉) by 1.3 ± 0.2 fold (n = 8 cells). Sample current responses are shown in Fig. 1A. The data are summarized in Fig. 1B.

Reduced potentiation is accounted for by increased constitutive activity in mutant receptors

A previous study noted increased constitutive activity in oocytes expressing the $\alpha 1\beta 3(Y143W)$ receptor (Eaton et al., 2016). Picrotoxin-sensitive outward current in the mutant receptor was $6 \pm 1\%$ of the response to saturating GABA, whereas no consistent changes in holding current during the application of picrotoxin are observed in oocytes expressing the wild-type $\alpha 1\beta 3$ receptor (Fig. 1A).

To test if the difference in constitutive activity can account for differences observed in potentiation by propofol, we simulated current responses using the concerted transition model (Chang and Weiss, 1999; Forman, 2012), and the affinity and efficacy estimates previously reported for $\alpha 1\beta 3$ and

$\alpha 1\beta 3(Y143W)$ receptors (Eaton et al., 2016). In these simulations, the presence of propofol is assumed to increase background activity (i.e., reduce L), which underlies the increase in the response to GABA (see *Materials and Methods* for details). In the wild-type receptor, the application of propofol produced a response with the mean peak amplitude of 0.4% of the response to saturating GABA. Following a conversion of the relative response to the units of open probability (Eq. 6) we calculate (Eq. 5) that exposure to propofol is expected to generate a background activity corresponding to L^* of 262. Comparison of the predicted responses to GABA at L of 1000 in the absence of propofol (Eq. 2), and at L^* of 262 (Eq. 3) yields a potentiation ratio of 3.5. The experimental potentiation ratio was 4.2 ± 1.6 (see above).

In the $\alpha 1\beta 3(Y143W)$ receptor, the application of propofol ($EC_{1.7\%}$) resulted in background activity corresponding to L^* of 12. From the predicted responses to GABA at L of 15.7 (control condition) and at L^* of 12 (in the presence of propofol), we obtain a simulated potentiation response ratio of 1.4. For comparison, the experimentally-determined potentiation ratio was 1.3 ± 0.2 .

The $\beta 3(Y143W)$ mutation has been shown to affect the activation properties of the $\alpha 1\beta 3$ receptor in the presence of propofol (Eaton et al., 2016), and it may be argued that this contributes to reduced potentiation in $\alpha 1\beta 3(Y143W)$. To address this possibility, we turned to the $\alpha 1(L263S)\beta 3$ receptor. The $\alpha 1(L263S)$ mutation has been shown to increase constitutive activity and to shift the activation concentration-response relationship to lower agonist concentrations in the $\alpha 1\beta 2\gamma 2$ ternary configuration (Chang et al., 1996; Chang and Weiss, 1999), but the mutation does not affect receptor affinity to propofol (Shin et al., 2018). Incorporation of the $\alpha 1(L263S)$ mutation drastically increased constitutive activity in the $\alpha 1\beta 3$ receptor ($P_{o, const} = 0.54 \pm 0.11$; $n = 7$). To test the effect of the mutation on potentiation, we coapplied 0.1 μM propofol, a concentration that elicited a response with a mean peak amplitude of 3% of the response to saturating GABA, with 0.001 μM GABA (EC_5). The combination of GABA + propofol elicited a response with the mean peak amplitude that was 1.5 ± 0.5 ($n = 5$) fold greater than the response to GABA alone. The predicted response ratio, simulated using Eqs. 3 and 5, was 1.6. We infer that increased constitutive activity in the mutant receptors leads to

reduced apparent potentiation in a quantitatively predictable manner.

Relationship between constitutive activity and potentiation

To gain a more general view of the relationship between constitutive activity and apparent potentiation, we modeled responses to GABA and the combination of GABA + propofol at different levels of constitutive activity. For convenience, we used the affinity (K_C) and efficacy (c) values for GABA and propofol estimated for the $\alpha 1\beta 3$ wild-type receptor (Eaton et al., 2016), and changed the value of the gating equilibrium constant of unliganded receptors (L).

We began by calculating the concentrations of GABA and propofol that when applied alone elicit a response with a peak amplitude of 5% of the response to saturating GABA (dubbed $EC_{5\%}$) at different values of L . The concerted transition model predicts that as constitutive activity increases (L decreases), the concentration of agonist needed to produce an $EC_{5\%}$ response decreases. We then simulated the response to the combination of the two agonists at each pair of concentrations. The results indicate that as constitutive activity increases, the simulated potentiation response ratio (predicted peak response in the presence of GABA + propofol / predicted peak response in the presence of GABA) decreases (Fig. 1C). Under conditions where half of the receptors are constitutively active ($P_{o, const} = 0.5$), combining GABA and propofol at concentrations that each separately produces a response that is 5% of the response to saturating GABA is predicted to result in approximately doubling of the response to GABA alone, i.e., an arithmetic sum of the responses to either agonist individually.

The relationship between constitutive activity, direct activation, and the potentiation ratio

The experiments and simulations above examined potentiation of GABA-elicited currents by the anesthetic propofol in the binary $\alpha 1\beta 3$ GABA_A receptor. We next turned to the ternary receptor formed

of concatemeric $\beta 2\alpha 1\gamma 2L$ and $\beta 2\alpha 1$ constructs. To determine how the intrinsic properties of the modulating drug affect potentiation, we first simulated current responses to GABA in the absence and presence of propofol, using the affinity and efficacy values reported previously for this receptor (Shin et al., 2018). The properties of the modulator were then altered by changing the nominal number of binding sites for the drug on the receptor. This is a simple and convenient way to modify the energetic contribution (ΔG) made by the modulating drug that links the number of binding sites (N) and gating efficacy (c) through $\Delta G = N_{\text{modulator}} RT \times \ln(c_{\text{modulator}})$.

Figure 2A shows that as the number of propofol binding sites (N_{PRO}) is reduced from 6 to 2, the simulated potentiation curves are shifted to higher propofol concentrations and saturate at lower amplitudes. These changes reflect the effect of reduced energetic contribution at lower N_{PRO} . We next evaluated the effect of altering the number of propofol binding sites on the potentiation response ratio. Figure 2B shows the simulated potentiation response ratio as a function of constitutive open probability at N_{PRO} constrained to 2-6. The calculations were done for the concatemeric ternary receptor activated by EC_5 GABA in the absence and presence of $EC_{5\%}$ propofol. The major finding is that the potentiation response ratios are predicted to be identical for all nominal N_{PRO} values. In other words, in the concerted transition model, coapplication of a modulator at $EC_{5\%}$ increases the response to EC_5 GABA by a factor that solely depends on the constitutive open probability of the receptor.

These simulations suggest that the extent of potentiation in a given receptor is identical for all combinations of agonists and modulators as long as the concentrations of the individual drugs are selected to generate a fixed, predetermined response when applied individually. To test this experimentally, we compared potentiation of concatemeric ternary receptors by propofol and pentobarbital. Both are allosteric GABAergic agents, but differ in their abilities to activate and modulate the $GABA_A$ receptor (Nourmahnad et al., 2016; Ruesch et al., 2012; Ziemba and Forman, 2016).

The experiments were conducted on wild-type concatemeric receptors ($P_{o,\text{const}} = 0.0001$; Akk et

al., 2018), and on receptors containing the gain-of-function $\alpha 1(L263S)$ mutation in a single $\alpha 1$ subunit ($P_{o, \text{const}} = 0.014$; Akk et al., 2018) or in both $\alpha 1$ subunits ($P_{o, \text{const}} = 0.10$; Shin et al., 2018). The concentrations of GABA, propofol and pentobarbital were selected to produce small ($\sim EC_{5-15}$) responses when applied individually. The experimental potentiation response ratios in the wild-type receptor were 9.3 ± 3.4 ($n = 6$ cells; GABA: EC_{10} , propofol: $EC_{6\%}$) and 9.7 ± 1.7 ($n = 6$ cells; GABA: EC_9 , pentobarbital: $EC_{6\%}$) for propofol and pentobarbital, respectively. For comparison, the predicted potentiation ratios calculated for the experimental EC values were 10.8 for propofol and 12.2 for pentobarbital. In the $\beta 2\alpha 1\gamma 2L + \beta 2\alpha 1(L263S)$ receptor, the potentiation response ratios were 2.9 ± 0.6 ($n = 9$ cells; GABA: EC_{12} , propofol: $EC_{6\%}$) and 4.3 ± 1.2 ($n = 6$ cells; GABA: EC_{13} , pentobarbital: $EC_{8\%}$) in the presence of propofol and pentobarbital, respectively. The predicted potentiation ratios at experimental EC values were 3.7 and 4.1 for propofol and pentobarbital, respectively. In the $\beta 2\alpha 1(L263S)\gamma 2L + \beta 2\alpha 1(L263S)$ receptor, the experimental potentiation response ratios were 2.1 ± 0.2 ($n = 5$ cells; GABA: EC_{11} , propofol: $EC_{7\%}$) and 2.1 ± 0.4 ($n = 6$ cells; GABA: EC_{13} , pentobarbital: $EC_{6\%}$) for propofol and pentobarbital, respectively. The predicted potentiation response ratios were 2.1 for propofol and 1.9 for pentobarbital. We infer that the degree of potentiation depends on the level of unliganded activity, and that it is further determined by the ability of the modulator to directly activate the receptor. Sample currents are shown in Fig. 3A-C. The data are summarized in Fig. 3D.

The effect of constitutive activity on isoboles of additivity

Energetic additivity between the effects of orthosteric and allosteric agonists underlies the curvilinear isoboles and apparent synergy when GABA and propofol are coapplied (Shin et al., 2017). To determine the effect of constitutive activity on apparent synergy, we modeled current responses from the $\alpha 1\beta 3$ receptor to combinations of GABA and propofol at different levels of constitutive activity. The data are presented as isobolograms with the target response having an open probability ($P_{o, \text{target}}$) of 0.5 (Fig. 4). We used receptor open probability in these simulations rather than a relative

current response because open probability has an absolute rather than relative value and is therefore more directly interpretable in the context of various cellular or behavioral endpoints.

The data indicate that the predicted deviation from the linear isobole of additivity decreases as constitutive activity increases (Fig. 4). If we assign "1/2[GABA]" as one-half of the concentration of GABA needed to generate a response with $P_{o,target}$ of 0.5, then the degree of synergy can be expressed through the concentration of propofol needed to potentiate the response to 1/2[GABA] to a P_o of 0.5. If the drug effects are strictly additive, this concentration ($[Propofol]_{linear}$) should be equal to 50% of the concentration of propofol that when applied alone generates a response with a P_o of 0.5. We have plotted in Fig. 5 the ratio between $[Propofol]_{linear}$ and the concentration of propofol predicted by the concerted transition model to produce a response with P_o of 0.5 in the presence of 1/2[GABA] ($[Propofol]_{CTM}$). The results indicate that this ratio decreases as constitutive activity increases. In other words, the concentrations of propofol predicted by the concerted transition model and the linear isobole needed to produce P_o of 0.5 in the presence of 1/2[GABA] become more similar as constitutive activity increases. The simulations also indicate that the ratio between $[Propofol]_{linear}$ and $[Propofol]_{CTM}$ at a given level of $P_{o,const}$ becomes smaller as the target P_o is reduced (Fig. 5).

Constitutive activity affects the difference in EC_{50} s for direct activation and potentiation

The EC_{50} for direct activation is greater than the EC_{50} for potentiation. This concept applies to both propofol-potentiation of receptors activated by a low, fixed concentration of GABA and GABA-potentiation of receptors activated by a low concentration of propofol. The shift in the EC_{50} s is due to the extra free energy provided by the secondary drug that acts by increasing background activity (Forman, 2012; Shin et al., 2018). Here, we have modeled the effect of constitutive activity on the EC_{50} s for direct activation and potentiation. For simplicity and convenience, we again used the activation parameters estimated for the wild-type $\alpha 1\beta 3$ GABA_A receptor (Eaton et al., 2016). We simulated the activation and potentiation data for propofol in the absence and presence of low GABA,

and for GABA in the absence and presence of low propofol. We confirmed the concept and predictions by comparing the EC_{50} s for GABA in the absence and presence of low propofol in two receptors ($\alpha 1\beta 3$ and $\alpha 1\beta 3(Y143W)$) differing in their level of constitutive activity.

The data summarized in Fig. 6A show that for any level of constitutive activity, the EC_{50} for direct activation by propofol is greater than the EC_{50} for propofol-potentiation of currents elicited by EC_5 GABA. However, the difference between the EC_{50} s decreases as the constitutive open probability increases. Figure 6B shows the simulated GABA EC_{50} s in the absence and presence of propofol that when applied alone produces a response of 5% of the response to saturating GABA. Again, the EC_{50} for direct activation is greater than the EC_{50} for potentiation. However, the difference is predicted to be smaller at high $P_{o, const}$.

To confirm this prediction experimentally, we compared GABA concentration-response relationships in the absence and presence of a low concentration of propofol in $\alpha 1\beta 3$ and $\alpha 1\beta 3(Y143W)$ receptors (Fig. 6C). In the wild-type receptor (estimated $P_{o, const} = 0.001$), the EC_{50} for GABA is 1.4 μM (Eaton et al., 2016). Coapplication of 4 μM propofol, that when applied alone generated a response with a P_o of 0.09 ± 0.03 , shifted the EC_{50} for GABA to $0.19 \pm 0.06 \mu M$ ($pEC_{50} = 6.75 \pm 0.15$; $n = 5$). The predicted EC_{50} for the wild-type receptor activated by GABA in the presence of propofol is 0.09 μM . In the $\alpha 1\beta 3(Y143W)$ mutant ($P_{o, const} = 0.06$), the GABA EC_{50} is 0.18 μM in the absence of other GABAergic drugs (Eaton et al., 2016). In the presence of 0.5 μM propofol (EC_8 , corresponds to P_o of 0.15), the EC_{50} for GABA was $0.15 \pm 0.14 \mu M$ ($pEC_{50} = 6.97 \pm 0.39$; $n = 12$). The simulated EC_{50} for GABA in the presence of propofol is 0.11 μM .

The prediction that propofol EC_{50} s for direct activation and potentiation of GABA-elicited currents are more similar at high $P_{o, const}$ (i.e., the prediction described in Fig. 6A) was serendipitously confirmed in our recent study (Shin et al., 2018). Specifically, we showed that in the $\beta 2\alpha 1\gamma 2L + \beta 2\alpha 1$ receptor ($P_{o, const} = 0.0001$), the propofol EC_{50} s were 73 μM for direct activation and 2.9 μM for potentiation of currents elicited by 10 μM GABA (EC_{17}). In receptors containing the $\alpha 1(L263S)$ mutation in both constructs ($P_{o, const} = 0.1$), the propofol EC_{50} for direct activation was 3.0 μM , and for

potentiation of receptors activated by 0.1 μM GABA (EC_{22}) 1.1 μM . The experimental EC_{50} ratios, 25 ± 4 for wild-type and 2.7 ± 0.3 for the mutant, are in general agreement with the predicted calculated EC_{50} ratios of 29 and 1.8 for the wild-type and mutant receptors, respectively.

Discussion

We have investigated potentiation of the GABA_A receptor in the framework of the concerted transition model. The model makes some specific predictions. These are: i) the potentiation ratio, expressed as the ratio of the peak amplitude in the presence of agonist + potentiator to the peak amplitude in the presence of agonist alone, decreases as the level of constitutive activity increases; ii) the apparent potentiating effects of different modulating drugs are equal and predictable, and depend only on the level of constitutive activity as long as the drugs are applied at concentrations that elicit a constant direct activating effect; and iii) reduced potentiation due to increased constitutive activity is associated with isobolograms that conform to simple additivity, and more similar concentration-response relationships for potentiation and direct activation. The predictions were verified by experimental data from binary and ternary GABA_A receptors.

Potentiating drugs are often characterized by their ability to enhance current responses to the transmitter, GABA. The concentration of GABA in such experiments is selected to produce a low, subsaturating response, usually between 5 and 20% of the response to saturating GABA (EC₅₋₂₀). A change in the potentiation response ratio, for example following introduction of a mutation, is typically considered to result from modifications to the interactions between the modulator and the receptor (effect on affinity), or from changes in the transduction mechanism (effect on gating). We show here that a change in constitutive open probability, i.e., the ability of the GABA_A receptor to gate in the absence of any GABAergic drugs, modifies the potentiation response ratio and accounts for observed reduction in potentiation of receptors containing the β (Y143W) or α (L263S) mutations. The simulations, confirmed by experimental data, indicate that at $P_{o, \text{const}} > 0.1$, the response to the combination of GABA + potentiator approaches the sum of the individual responses to the transmitter and the potentiating drug (Figs. 1C, 2B). Increased constitutive activity is associated with increases in apparent affinity and efficacy of direct activation (Akk et al., 2018; Chang and Weiss, 1999; Ehlert, 2014a; Forman, 2012). Therefore, receptors with high $P_{o, \text{const}}$ exhibit efficient direct activation but

weak potentiation.

Selective reduction or loss of potentiation by allosteric drugs in receptors showing increased spontaneous activity has been observed previously. Incorporation of the L259S mutation in TM2 of the $\beta 2$ subunit produced receptors that exhibited large leak current and direct activation by pentobarbital and propofol. However, potentiation of EC_{20} GABA currents by these allosteric agents was drastically reduced compared to that in wild-type (Thompson et al., 1999). Stewart and coworkers (Stewart et al., 2008) showed that introduction of the $\alpha 1$ (M236W) mutation increases constitutive activity in the $\alpha 1\beta 2\gamma 2L$ receptor. The anesthetic etomidate efficaciously activated the mutant receptors, but was a weak potentiator of GABA-activated receptors. GABA_A receptors containing the ϵ subunit are directly activated by pentobarbital and propofol but show little potentiation of GABA-elicited currents (Davies et al., 1997). Given that ϵ -containing receptors are constitutively active ($P_{o, \text{const}} > 0.2$; (Neelands et al., 1999; Thompson et al., 2002)), we propose that the apparent resistance to the modulatory actions of anesthetics in ϵ -containing receptors is a consequence of high $P_{o, \text{const}}$ and not because of impaired binding of the anesthetic drugs.

Our simulations, confirmed by experimental data, indicate that the extent of potentiation does not depend on the intrinsic properties of a potentiating drug as long as the potentiator is applied at a concentration that produces a fixed direct activating effect. In other words, the concerted transition model predicts that all allosteric potentiating drugs modulate the response to transmitter by an identical factor provided the drugs are applied at concentrations that, when applied alone, elicit a direct activating effect of the same magnitude. We have confirmed this prediction experimentally by comparing potentiation of wild-type and mutated receptors by propofol and pentobarbital (Fig. 3). Furthermore, for a wide range of $P_{o, \text{const}}$, the potentiation response ratios are not sensitive to the ability of GABA to activate the receptor, per se, provided the potentiator is tested at the same fractional GABA response, i.e., constant EC value. Thus, the potentiation response ratio has a predictable and identical value for various agonist-modulator combinations, as long as the orthosteric agonist and the allosteric potentiator each elicit a fixed-amplitude response. However, the potentiation

response ratio depends on $P_{o, \text{const}}$, which is an intrinsic property of the receptor.

These findings may appear unintuitive but are easily understood in the framework of the concerted transition model. In this model (Ehlert, 2014b; Forman, 2012; Monod et al., 1965), the binding of transmitter makes an energetic contribution to stabilize the open state whereas the application of the allosteric potentiator can be viewed as reducing the free energy difference to be overcome by the transmitter. In this regard, as long as the energetic contribution is similar, the nature of the allosteric drug is of little matter, as we have recently shown for the shift in GABA EC_{50} produced by various allosteric agents (Akk et al., 2018). And conversely, the transmitter can be considered to increase background activity and reduce the free energy difference to be overcome by the allosteric drug (Shin et al., 2018).

Isobolographic analysis can be used to characterize drug interactions (Loewe, 1953; Tallarida, 2006). We previously showed that the combination of GABA + propofol exhibits apparent synergy as the data representing activity for the drug combination fall outside the linear isobole of additivity (Shin et al., 2017). We now show that the predicted isoboles become more linear, i.e., less synergistic, as constitutive activity increases. Less apparent synergy is also observed when the target effect is reduced and the difference between $P_{o, \text{const}}$ and $P_{o, \text{target}}$ becomes smaller. These findings make an interesting prediction. It is predicted that drug combinations show more apparent synergy for endpoints requiring a higher target P_o such as loss of righting, whereas endpoints associated with a smaller potentiating effect on the GABA_A receptor, e.g., anxiolysis, are expected to follow linear isoboles of additivity. Likewise, receptors that are constitutively active (e.g., ϵ subunit-containing receptors) are predicted to mediate effects showing less apparent synergy in the presence of combinations of agonists. We also note that in constitutively active receptors, direct activation, rather than potentiation of transmitter-gated activity, is the major contributor of the actions of GABAergic anesthetics.

In sum, we have shown that constitutive activity can affect the extent of potentiation and that in receptors with $P_{o, \text{const}} > 0.1$, currents elicited by an orthosteric agonist are minimally potentiated by

allosteric potentiators even when efficiently directly activated by the drugs. We also showed that the potentiating effects of allosteric modulators are identical provided the modulators are applied at concentrations that elicit the same direct activating effect. The downstream corollaries of increased constitutive activity and reduced apparent potentiation are more similar direct activation and potentiation curves for the allosteric drugs and drug interactions that conform to additivity rather than synergy.

Acknowledgments

We thank Dr. Joe Henry Steinbach for valuable suggestions.

Authorship contributions

Participated in research design: Evers, Akk

Conducted experiments: Germann, Shin, Kuhrau, Johnson

Contributed new reagents or analytical tools: N/A

Performed data analysis: Germann, Shin, Kuhrau, Johnson, Akk

Wrote or contributed to the writing of the manuscript: Germann, Shin, Kuhrau, Johnson, Evers, Akk

References

- Akk G, Shin DJ, Germann AL and Steinbach JH (2018) GABA_A receptor activation in the allosteric coagonist model framework: relationship between EC₅₀ and basal activity. *Mol Pharmacol* **93**(2): 90-100.
- Bouzat C (2012) New insights into the structural bases of activation of Cys-loop receptors. *J Physiol Paris* **106**(1-2): 23-33.
- Bracamontes J, McCollum M, Esch C, Li P, Ann J, Steinbach JH and Akk G (2011) Occupation of either site for the neurosteroid allopregnanolone potentiates the opening of the GABA_A receptor induced from either transmitter binding site. *Mol Pharmacol* **80**(1): 79-86.
- Bracamontes JR and Steinbach JH (2009) Steroid interaction with a single potentiating site is sufficient to modulate GABA_A receptor function. *Mol Pharmacol* **75**(4): 973-981.
- Carlson BX, Engblom AC, Kristiansen U, Schousboe A and Olsen RW (2000) A single glycine residue at the entrance to the first membrane-spanning domain of the γ -aminobutyric acid type A receptor β 2 subunit affects allosteric sensitivity to GABA and anesthetics. *Mol Pharmacol* **57**(3): 474-484.
- Chang Y, Wang R, Barot S and Weiss DS (1996) Stoichiometry of a recombinant GABA_A receptor. *J Neurosci* **16**(17): 5415-5424.
- Chang Y and Weiss DS (1999) Allosteric activation mechanism of the α 1 β 2 γ 2 γ -aminobutyric acid type A receptor revealed by mutation of the conserved M2 leucine. *Biophys J* **77**(5): 2542-2551.
- Davies PA, Hanna MC, Hales TG and Kirkness EF (1997) Insensitivity to anaesthetic agents conferred by a class of GABA_A receptor subunit. *Nature* **385**(6619): 820-823.
- Eaton MM, Cao LQ, Chen Z, Franks NP, Evers AS and Akk G (2015) Mutational analysis of the putative high-affinity propofol binding site in human β 3 homomeric GABA_A receptors. *Mol Pharmacol* **88**(4): 736-745.

- Eaton MM, Germann AL, Arora R, Cao LQ, Gao X, Shin DJ, Wu A, Chiara DC, Cohen JB, Steinbach JH, Evers AS and Akk G (2016) Multiple non-equivalent interfaces mediate direct activation of GABA_A receptors by propofol. *Curr Neuropharmacol* **14**(7): 772-780.
- Ehlert FJ (2014a) Affinity and efficacy of orthosteric ligands at ligand-gated ion channels, in *Affinity and Efficacy* pp 73-160, World Scientific Publishing Co. Pte. Ltd., Singapore.
- Ehlert FJ (2014b) Analysis of allosteric interactions at ligand-gated ion channels, in *Affinity and Efficacy* pp 179-249, World Scientific Publishing Co. Pte. Ltd., Singapore.
- Forman SA (2012) Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate. *Curr Opin Anaesthesiol* **25**(4): 411-418.
- Hales TG and Lambert JJ (1991) The actions of propofol on inhibitory amino acid receptors of bovine adrenomedullary chromaffin cells and rodent central neurones. *Br J Pharmacol* **104**(3): 619-628.
- Jayakar SS, Zhou X, Chiara DC, Dostalova Z, Savechenkov PY, Bruzik KS, Dailey WP, Miller KW, Eckenhoff RG and Cohen JB (2014) Multiple propofol-binding sites in a γ -aminobutyric acid type A receptor (GABA_AR) identified using a photoreactive propofol analog. *J Biol Chem* **289**(40): 27456-27468.
- Karlin A (1967) On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. *J Theor Biol* **16**(2): 306-320.
- Krasowski MD, Nishikawa K, Nikolaeva N, Lin A and Harrison NL (2001) Methionine 286 in transmembrane domain 3 of the GABA_A receptor β subunit controls a binding cavity for propofol and other alkylphenol general anesthetics. *Neuropharmacology* **41**(8): 952-964.
- Loewe S (1953) The problem of synergism and antagonism of combined drugs. *Arzneimittelforschung* **3**(6): 285-290.
- Monod J, Wyman J and Changeux JP (1965) On the nature of allosteric transitions: a plausible model. *J Mol Biol* **12**: 88-118.

- Neelands TR, Fisher JL, Bianchi M and Macdonald RL (1999) Spontaneous and γ -aminobutyric acid (GABA)-activated GABA_A receptor channels formed by ϵ subunit-containing isoforms. *Mol Pharmacol* **55**(1): 168-178.
- Nourmahnad A, Stern AT, Hotta M, Stewart DS, Ziemba AM, Szabo A and Forman SA (2016) Tryptophan and cysteine mutations in M1 helices of $\alpha 1\beta 3\gamma 2L$ γ -aminobutyric acid type A receptors indicate distinct intersubunit sites for four intravenous anesthetics and one orphan site. *Anesthesiology* **125**(6): 1144-1158.
- Richardson JE, Garcia PS, O'Toole KK, Derry JM, Bell SV and Jenkins A (2007) A conserved tyrosine in the $\beta 2$ subunit M4 segment is a determinant of γ -aminobutyric acid type A receptor sensitivity to propofol. *Anesthesiology* **107**(3): 412-418.
- Ruesch D, Neumann E, Wulf H and Forman SA (2012) An allosteric coagonist model for propofol effects on $\alpha 1\beta 2\gamma 2L$ γ -aminobutyric acid type A receptors. *Anesthesiology* **116**(1): 47-55.
- Shin DJ, Germann AL, Johnson AD, Forman SA, Steinbach JH and Akk G (2018) Propofol is an allosteric agonist with multiple binding sites on concatemeric ternary GABA_A receptors. *Mol Pharmacol* **93**(2): 178-189.
- Shin DJ, Germann AL, Steinbach JH and Akk G (2017) The actions of drug combinations on the GABA_A receptor manifest as curvilinear isoboles of additivity. *Mol Pharmacol* **92**(5): 556-563.
- Stewart D, Desai R, Cheng Q, Liu A and Forman SA (2008) Tryptophan mutations at azi-etomidate photo-incorporation sites on $\alpha 1$ or $\beta 2$ subunits enhance GABA_A receptor gating and reduce etomidate modulation. *Mol Pharmacol* **74**(6): 1687-1695.
- Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. *J Pharmacol Exp Ther* **319**(1): 1-7.
- Thompson SA, Bonnert TP, Cagetti E, Whiting PJ and Wafford KA (2002) Overexpression of the GABA_A receptor ϵ subunit results in insensitivity to anaesthetics. *Neuropharmacology* **43**(4): 662-668.

- Thompson SA, Smith MZ, Wingrove PB, Whiting PJ and Wafford KA (1999) Mutation at the putative GABA_A ion-channel gate reveals changes in allosteric modulation. *Br J Pharmacol* **127**(6): 1349-1358.
- Yip GM, Chen ZW, Edge CJ, Smith EH, Dickinson R, Hohenester E, Townsend RR, Fuchs K, Sieghart W, Evers AS and Franks NP (2013) A propofol binding site on mammalian GABA_A receptors identified by photolabeling. *Nat Chem Biol* **9**(11): 715-720.
- Ziemba AM and Forman SA (2016) Correction for inhibition leads to an allosteric co-agonist model for pentobarbital modulation and activation of $\alpha 1\beta 3\gamma 2L$ GABA_A Receptors. *PLoS One* **11**(4): e0154031.

Footnotes

This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grants RO1GM108580 and RO1GM108799]; the Center for the Investigation of Membrane Excitability Diseases at Washington University [Grant CIMED-17-03]; and funds from the Taylor Family Institute for Innovative Psychiatric Research.

Reprint requests to: Gustav Akk, Department of Anesthesiology, Washington University, Campus Box 8054, 660 S. Euclid Ave, St. Louis, MO 63110. Email: akk@morpheus.wustl.edu

Legends for Figures

Figure 1. Constitutive activity modifies receptor potentiation by propofol. (A) Sample current responses from $\alpha 1\beta 3$ wild-type and $\alpha 1\beta 3(Y143W)$ mutant receptors. To measure potentiation, the drug concentrations were 0.3 μM GABA and 1 μM propofol (PRO) for wild-type and 0.02 μM GABA and 0.1 μM propofol for $\alpha 1\beta 3(Y143W)$. For each receptor, sample traces showing responses to saturating GABA (dashed lines; 30 μM for wild-type, 10 μM for $\alpha 1\beta 3(Y143W)$) and 300 μM picrotoxin (PTX) are also shown. Recovery from picrotoxin-elicited block of constitutive activity in the mutant receptor was complete following a 10-min washout. Only the first 100 s of the trace are shown. (B) Summary of potentiation data from $\alpha 1\beta 3$ and $\alpha 1\beta 3(Y143W)$ receptors. The graph shows data from each cell tested (hollow circles) and mean \pm S.D. (filled circles and error bars), normalized to responses to saturating GABA. The number of cells tested was 6 for wild-type and 8 for the mutant. (C) Potentiation of GABA-activated $\alpha 1\beta 3$ receptors by propofol was simulated at GABA and propofol concentrations eliciting responses equal to 5% of the response to saturating GABA. The potentiation response ratio was calculated as the ratio of the response to the combination of GABA + propofol to that to GABA alone. The simulated potentiation response ratio decreases as the level of constitutive activity increases. The dashed line shows the response to GABA alone (1).

Figure 2. The simulated relationship between the properties of a potentiator and the extent of potentiation. (A) Simulated concentration-response curves for potentiation of EC_5 GABA-activated wild-type $\beta 2\alpha 1\gamma 2\text{L} + \beta 2\alpha 1$ receptors by propofol. The K_{PRO} was 21 μM and c_{PRO} was 0.22 (Shin et al., 2018). The number of propofol binding sites (N_{PRO}) was varied from 2 to 6 (bottom to top), to mimic potentiation by different modulators. (B) Simulated potentiation response ratios for receptors activated by EC_5 GABA and potentiated by propofol at a concentration that, when applied alone, elicits a response with the same peak current ($\text{EC}_{5\%}$), at different $P_{\text{o, const}}$. The simulations show that the potentiation response ratio is identical for all imposed values of N_{PRO} , suggesting that different

allosteric potentiators potentiate the receptor by the same degree as long as the direct-activating response to the potentiator is constant. The dashed line shows the response to GABA alone (1).

Figure 3. The relationship between constitutive activity, direct activation, and the extent of potentiation. (A) Sample current traces from the wild-type $\beta 2\alpha 1\gamma 2L+\beta 2\alpha 1$ receptor. The receptors were exposed to GABA (EC_{9-10}), propofol (PRO; EC_6) or pentobarbital (PEB; EC_6), and the combination of GABA + propofol or GABA + pentobarbital. (B) Sample current traces from the $\beta 2\alpha 1\gamma 2L+\beta 2\alpha 1(L263S)$ receptor. The receptors were exposed to GABA (EC_{12-13}), propofol (PRO; EC_6) or pentobarbital (PEB; $EC_{8.5}$), and the combination of GABA + propofol or GABA + pentobarbital. (C) Sample current traces from the $\beta 2\alpha 1(L263S)\gamma 2L+\beta 2\alpha 1(L263S)$ receptor. The receptors were exposed to GABA (EC_{11-13}), propofol (PRO; EC_7) or pentobarbital (PEB; EC_6), and the combination of GABA + propofol or GABA + pentobarbital. In A-C, responses to 300 μM picrotoxin (PTX) and saturating GABA (the dashed trace) from a same cell are shown to demonstrate differences in constitutive activity in the wild-type and mutant receptors. The mean $P_{o,const}$ is 0.0001 in the wild-type receptor (Akk et al., 2018), 0.014 in $\beta 2\alpha 1\gamma 2L+\beta 2\alpha 1(L263S)$ (Akk et al., 2018), and 0.01 in $\beta 2\alpha 1(L263S)\gamma 2L+\beta 2\alpha 1(L263S)$ (Shin et al., 2018). (D) Summary of potentiation data from $\beta 2\alpha 1\gamma 2L+\beta 2\alpha 1$, $\beta 2\alpha 1\gamma 2L+\beta 2\alpha 1(L263S)$ and $\beta 2\alpha 1(L263S)\gamma 2L+\beta 2\alpha 1(L263S)$ receptors. The graph shows data from each cell tested (hollow circles) and mean \pm S.D. (filled circles and error bars), normalized to responses to saturating GABA. The number of cells tested was 6 for wild-type tested with propofol or pentobarbital. In $\beta 2\alpha 1\gamma 2L+\beta 2\alpha 1(L263S)$, the number of cells was 6 for propofol and pentobarbital. In $\beta 2\alpha 1(L263S)\gamma 2L+\beta 2\alpha 1(L263S)$, the number of cells was 5 for propofol and 6 for pentobarbital. The findings indicate that i) apparent potentiation is greater in the receptor with less constitutive activity (wild-type), and ii) the extent of potentiation is similar for propofol and pentobarbital.

Figure 4. Constitutive activity modifies the predicted isoboles of additivity. The figure shows

simulated isobolograms for activation of the $\alpha 1\beta 3$ receptor by GABA, propofol, and combinations of GABA + propofol with the target open probability of 0.5 at different levels of constitutive activity. The straight line in each panel represents the linear isobole traditionally associated with additive effects of the two drugs. The data points show the simulated isoboles based on energetic additivity using the affinity and efficacy data published previously (Eaton et al., 2016). The K_{GABA} was 1.6 μM , C_{GABA} was 0.02, K_{PRO} was 4.7 μM , and C_{PRO} was 0.24. The numbers of binding sites were constrained to 2 and 5 for GABA and propofol, respectively. The data indicate that as $P_{o,const}$ increases the predicted isoboles approach linearity.

Figure 5. Constitutive activity is predicted to affect apparent synergy. Constitutive open probability affects the simulated ratio of $[Propofol]_{linear}$ over $[Propofol]_{CTM}$, defined as the displacement between the linear isobole of additivity and the isobole predicted by the concerted transition model. A ratio greater than unity (shown with a dashed line) indicates that energetic additivity predicts a synergistic interaction between GABA and propofol. The simulations indicate that the apparent degree of synergy decreases as the difference between the target ($P_{o,target}$) and basal open probabilities ($P_{o,const}$) decreases.

Figure 6. Constitutive activity affects the positions of the concentration-response relationships for direct activation and potentiation. (A) Simulated propofol EC_{50} values for direct activation and potentiation of receptors activated by EC_5 GABA at different levels of constitutive activity. The simulations were done using the affinity and efficacy values determined previously for the wild-type $\alpha 1\beta 3$ receptor (Eaton et al., 2016). The K_{GABA} was 1.6 μM , C_{GABA} was 0.02, K_{PRO} was 4.7 μM , and C_{PRO} was 0.24. The numbers of binding sites were constrained to 2 and 5 for GABA and propofol, respectively. (B) Simulated EC_{50} values for activation by GABA in the absence and presence of propofol at concentrations that elicited a response that was 5% of the response to saturating GABA at the given $P_{o,const}$. (C) Concentration-response curves for GABA in the absence

and presence of 4 μM (wild-type) or 0.5 μM propofol ($\alpha 1\beta 3(\text{Y}143\text{W})$). The data points (black circles: wild-type; blue squares: mutant) show mean \pm S.D. from 5-12 cells. The solid-line curves show simulations using the averaged fitting parameters: wild-type, GABA + propofol (black line): $Y_{\text{min}} = 0.09$, $\text{EC}_{50} = 0.19 \mu\text{M}$, $n_{\text{H}} = 1.16$; $\alpha 1\beta 3(\text{Y}143\text{W})$, GABA + propofol (blue line): $Y_{\text{min}} = 0.08$, $\text{EC}_{50} = 0.15 \mu\text{M}$, $n_{\text{H}} = 1.01$. The dashed black (wild-type) and blue (mutant) lines show the concentration-response data for GABA alone with EC_{50} s of 1.4 μM for wild-type and 0.18 μM for mutant from a prior study (Eaton et al., 2016).

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

